We are live on ! Find out more
MITO

Stealth BioTherapeutics Corp. ADS

Delisted

MITO was delisted on the 15th of November, 2022.

10 hedge funds and large institutions have $947K invested in Stealth BioTherapeutics Corp. ADS in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

100% more funds holding

Funds holding: 510 (+5)

26% more capital invested

Capital invested by funds: $752K → $947K (+$195K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
10
Holders Change
+5
Holders Change %
+100%
% of All Funds
0.22%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
Reduced
2
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
PM
1
Prosight Management
Texas
$417K +$748K +336,167 New
BBHC
2
Brown Brothers Harriman & Co
New York
$217K
Renaissance Technologies
3
Renaissance Technologies
New York
$158K +$284K +127,800 New
IC
4
Ikarian Capital
Texas
$47K
Millennium Management
5
Millennium Management
New York
$45K +$80.1K +36,030 New
PC
6
PA Capital
Virginia
$28K +$49.9K +22,461 New
Two Sigma Investments
7
Two Sigma Investments
New York
$15K +$27.6K +12,434 New
Deutsche Bank
8
Deutsche Bank
Germany
$12K +$21.8K +9,800 New
Morgan Stanley
9
Morgan Stanley
New York
$7K -$11.1K -5,000 -45%
UBS Group
10
UBS Group
Switzerland
$1K -$14.7K -6,600 -94%

MITO Hedge Fund Activity: Q1 2020 in Review

10 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Stealth BioTherapeutics Corp. ADS (MITO) for Q1 2020, worth a combined $947K — up 26% from $752K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new MITO positions and 1 closed out — a net gain of 5 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Prosight Management, opening a new position worth an estimated $748K. The largest seller was UBS Group, cutting an estimated $14.7K.

  • 10 institutional investors held Stealth BioTherapeutics Corp. ADS (MITO) as of Q1 2020, up from 5 in Q4 2019.
  • Funds reported $947K of Stealth BioTherapeutics Corp. ADS stock for Q1 2020, up 26% quarter-over-quarter.
  • 6 funds opened new Stealth BioTherapeutics Corp. ADS positions in Q1 2020 and 1 closed out, a net change of +5 holders.
  • The largest Stealth BioTherapeutics Corp. ADS buyer in Q1 2020 was Prosight Management, an estimated $748K added.
  • The largest Stealth BioTherapeutics Corp. ADS seller in Q1 2020 was UBS Group, an estimated $14.7K sold.

Based on aggregated 13F filings for Q1 2020.